Quidel in Preliminary Pact With NIH on Virus Tests

July 31, 2020, 3:37 PM

Quidel says it has entered a preliminary letter contract with NIH to support expansion of manufacturing capacity for assays that test for SARS-CoV-2 Antigen.

  • Quidel and NIH endeavor to enter into a definitive agreement to support the initiative by mid-September
  • Company says NIH RADx-ATP investment would support upgrade and addition of manufacturing lines, expanding capacity for test cassettes from approximately 84 million cassettes per year to in excess of 220 million cassettes per year

To view the source of this information click here

To contact the reporter on this story:
Erin McClam in New York at emcclam@bloomberg.net

To contact the ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.